Medicare seniors get cheaper non-opioid pain drugs, opioid gatekeeping ends
S. 475 — Alternatives to PAIN Act · Filed by Thom Tillis (R-NC) · 36 cosponsors · Introduced Feb 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare Part D to make non-opioid pain management drugs more accessible by eliminating deductibles, placing them on the lowest cost-sharing tier, and prohibiting step therapy (requiring patients to try opioids first) and prior authorization requirements for qualifying drugs. The bill applies to FDA-approved non-opioid pain drugs with no therapeutic equivalent and a monthly cost below a specialty-tier threshold, starting January 1, 2026.
Why we flagged it
The bill's operative mechanism is a cost and access mandate for non-opioid pain drugs under Medicare Part D, designed to shift prescribing away from opioids by removing financial and procedural barriers.
What the text implies
- The bill defines 'qualifying' drugs narrowly (no therapeutic equivalent, cost threshold), which may exclude some non-opioid alternatives and create incentives for manufacturers to price strategically below the specialty-tier threshold to gain automatic coverage.
- Elimination of prior authorization and step therapy removes plan-level utilization management entirely for qualifying drugs, potentially increasing volume and spending without clinical review, though this may be intentional to overcome opioid-prescribing inertia.
The full analysis lists 5 implications of this text.
Who stands to gain
Non-opioid pain management drug manufacturers (e.g., Pfizer, Bristol Myers Squibb, Johnson & Johnson; Specialty pharmaceutical companies with non-opioid pain products; Medicare beneficiaries (reduced out-of-pocket costs)